Incannex Healthcare Inc
IXHL0.451USD
+0.065+16.94%
取引時間 （ET）15分遅れの株価
8.02M時価総額
損失額直近12ヶ月PER
詳細情報 Incannex Healthcare Inc 企業名
Incannex Healthcare Inc. is a clinical-stage pharmaceutical development company. The Company is developing medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for the treatment of obstructive sleep apnea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, and pain, among other indications. The Company’s diversified portfolio includes 28 distinct research and development (R&D) programs, and six clinical trials underway. Its clinical projects include IHL-42X Obstructive Sleep Apnea, IHL-675A Inflammatory Lung Disease, IHL-675A Rheumatoid Arthritis, IHL-675A Inflammatory Bowel Disease, IHL-216A Concussion and TBI, PSI-GAD Psilocybin for anxiety, MedChew GB Post-herpatic Neuralgia and MedChew -1401 Pain and Spasticity in Multiple Sclerosis.
企業情報
企業コードIXHL
会社名Incannex Healthcare Inc
上場日Mar 18, 2022
最高経営責任者「CEO」Mr. Joel Latham
従業員数9
証券種類Ordinary Share
決算期末Mar 18
本社所在地8 Century Circuit
都市
証券取引所NASDAQ Capital Market Consolidated
国Australia
郵便番号2153
電話番号61409840786
ウェブサイト
企業コードIXHL
上場日Mar 18, 2022
最高経営責任者「CEO」Mr. Joel Latham
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Joel Latham
Mr. Joel Latham
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
1.24M
-21.24%
Dr. George Anastassov
Dr. George Anastassov
Non-Executive Independent Director
Non-Executive Independent Director
744.72K
-3.25%
Mr. Lekhram Changoer
Mr. Lekhram Changoer
Chief Technology Officer
Chief Technology Officer
639.55K
--
Mr. Peter Widdows
Mr. Peter Widdows
Non-Executive Independent Director
Non-Executive Independent Director
245.85K
-9.23%
Mr. Joseph Swan
Mr. Joseph Swan
Chief Financial Officer, Controller, Treasurer, Company Secretary
Chief Financial Officer, Controller, Treasurer, Company Secretary
17.93K
-89.40%
Mr. Troy Valentine
Mr. Troy Valentine
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Dr. Luigi M. (Lou) Barbato, M.D.
Dr. Luigi M. (Lou) Barbato, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Robert B. Clark
Mr. Robert B. Clark
Non-Executive Independent Director
Non-Executive Independent Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Joel Latham
Mr. Joel Latham
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
1.24M
-21.24%
Dr. George Anastassov
Dr. George Anastassov
Non-Executive Independent Director
Non-Executive Independent Director
744.72K
-3.25%
Mr. Lekhram Changoer
Mr. Lekhram Changoer
Chief Technology Officer
Chief Technology Officer
639.55K
--
Mr. Peter Widdows
Mr. Peter Widdows
Non-Executive Independent Director
Non-Executive Independent Director
245.85K
-9.23%
Mr. Joseph Swan
Mr. Joseph Swan
Chief Financial Officer, Controller, Treasurer, Company Secretary
Chief Financial Officer, Controller, Treasurer, Company Secretary
17.93K
-89.40%
Mr. Troy Valentine
Mr. Troy Valentine
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
収益内訳
FY2025Q1
FY2024
FY2024Q4
FY2022
データなし
地域別USD
会社名
収益
比率
Australia
74.00K
0.00%
事業別
地域別
データなし
株主
更新時刻: Wed, Jul 16
更新時刻: Wed, Jul 16
株主統計
種類
株主統計
株主統計
比率
Great Point Capital LLC
6.55%
L1 Capital Global Opportunities Master Fund Ltd.
6.55%
S.H.N. Financial Investments Ltd
6.55%
Latham (Joel)
4.22%
Valentine (Troy Robert)
2.95%
Other
73.17%
株主統計
株主統計
比率
Great Point Capital LLC
6.55%
L1 Capital Global Opportunities Master Fund Ltd.
6.55%
S.H.N. Financial Investments Ltd
6.55%
Latham (Joel)
4.22%
Valentine (Troy Robert)
2.95%
Other
73.17%
種類
株主統計
比率
Corporation
13.11%
Individual Investor
13.03%
Investment Advisor
8.09%
Hedge Fund
0.35%
Research Firm
0.18%
Investment Advisor/Hedge Fund
0.03%
Other
65.22%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
39
10.24M
34.78%
+3.35M
2025Q1
36
6.86M
34.69%
+1.54M
2024Q4
34
5.22M
29.25%
-10.87K
2024Q3
35
5.23M
32.43%
+928.92K
2024Q2
32
5.32M
33.29%
+935.04K
2024Q1
33
4.38M
27.39%
+2.50M
2023Q4
26
4.32M
27.01%
+2.81M
2023Q3
13
32.37K
0.05%
-34.33K
2023Q2
11
12.21K
0.02%
-63.09K
2023Q1
10
20.53K
0.03%
-60.83K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Great Point Capital LLC
1.93M
6.55%
+1.93M
--
Apr 09, 2025
L1 Capital Global Opportunities Master Fund Ltd.
1.93M
6.55%
+460.27K
+31.34%
Apr 09, 2025
S.H.N. Financial Investments Ltd
1.93M
6.55%
+1.93M
--
Apr 09, 2025
Latham (Joel)
1.24M
4.22%
-335.00K
-21.24%
Apr 09, 2025
Valentine (Troy Robert)
869.01K
2.95%
-167.50K
-16.16%
Apr 09, 2025
Anastassov (George)
744.72K
2.53%
-25.00K
-3.25%
Apr 09, 2025
Changoer (Lekhram)
639.55K
2.17%
--
--
Apr 09, 2025
AdvisorShares Investments, LLC
295.03K
1%
+129.54K
+78.27%
Mar 31, 2025
Widdows (Peter)
245.85K
0.84%
-25.00K
-9.23%
Apr 09, 2025
Citadel Advisors LLC
102.87K
0.35%
+102.87K
--
Mar 31, 2025
詳細を見る
関連ETF
更新時刻: Sat, Aug 2
更新時刻: Sat, Aug 2
銘柄名
比率
AdvisorShares Psychedelics ETF
0.73%
Amplify Alternative Harvest ETF
0%
AdvisorShares Psychedelics ETF
比率0.73%
Amplify Alternative Harvest ETF
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
